ERBB2 and glioblastoma: Although completed trials for glioblastoma with anti-EGFRvIII CAR T (NCT02209376)29, (NCT01454596)30,31, anti-HER2 CAR T (NCT01109095)32, and ongoing trials with anti-IL-13Rα2 CAR T (NCT02208362)33,34 reported promising results, there are still several safety concerns to be addressed and areas that need further improvement35.